Mesoblast (NASDAQ:MESO) Stock Rating Upgraded by Cantor Fitzgerald

Mesoblast (NASDAQ:MESO - Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating in a note issued to investors on Thursday,Zacks.com reports.

MESO has been the topic of a number of other research reports. Piper Sandler lifted their price target on shares of Mesoblast from $11.00 to $15.00 and gave the company an "overweight" rating in a report on Thursday, December 19th. Jefferies Financial Group lowered shares of Mesoblast from a "buy" rating to a "hold" rating in a report on Monday, December 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $13.50.

Mesoblast Price Performance

Shares of MESO traded up $0.38 during mid-day trading on Thursday, reaching $20.44. The company had a trading volume of 153,432 shares, compared to its average volume of 463,174. The firm has a fifty day simple moving average of $15.85 and a 200-day simple moving average of $10.72. Mesoblast has a fifty-two week low of $1.75 and a fifty-two week high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Mesoblast

Hedge funds and other institutional investors have recently modified their holdings of the stock. R Squared Ltd bought a new stake in shares of Mesoblast in the 4th quarter worth about $30,000. Signaturefd LLC boosted its holdings in shares of Mesoblast by 128.7% in the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company's stock valued at $45,000 after buying an additional 3,099 shares during the period. Perkins Coie Trust Co boosted its holdings in shares of Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company's stock valued at $94,000 after buying an additional 1,500 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Mesoblast by 22.1% in the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock valued at $133,000 after buying an additional 1,213 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Mesoblast in the 4th quarter valued at about $134,000. Institutional investors own 1.43% of the company's stock.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.